More Web Proxy on the site http://driver.im/

Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma Who Had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report (Q41767944)

From Wikidata

Jump to navigation Jump to search

scientific article published on May 15, 2012

Language	Label	Description	Also known as
English	Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma Who Had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report	scientific article published on May 15, 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

0 references

Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report (English)

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma Who Had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report (English)

1 reference

10.4021/JOCMR816E

https://api.crossref.org/works/10.4021/JOCMR816E

4 January 2025

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22719810

4 January 2025

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22719810

4 January 2025

author name string

Su Jin Lee

1

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Ho Sung Lee

2

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Jae Sung Choi

3

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Ju Ock Na

4

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Ki Hyun Seo

5

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Mi Hye Oh

6

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Sung Shick Jou

7

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22719810

4 January 2025

publication date

15 May 2012

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

full work available at URL

https://www.jocmr.org/index.php/JOCMR/article/download/1016/483

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22719810

4 January 2025

https://europepmc.org/articles/PMC3376882

HyperText Markup Language

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22719810

4 January 2025

https://europepmc.org/articles/PMC3376882?pdf=render

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A22719810

4 January 2025

http://www.jocmr.org/index.php/JOCMR/article/download/1016/483

1 reference

10.4021/JOCMR816E

https://api.crossref.org/works/10.4021/JOCMR816E

4 January 2025

Journal of Clinical Medicine Research

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

216-220

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Bronchioloalveolar Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

6 June 2018

IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

18 August 2018

Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3376882

18 August 2018

Identifiers

10.4021/JOCMR816E

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41767944&oldid=2294631193"